Merck-FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

默克(US:MRK) Businesswire·2025-11-22 05:12

公司动态 - 默克公司宣布其KEYTRUDA®（帕博利珠单抗）及KEYTRUDA QLEX™（帕博利珠单抗和透明质烷酶阿尔法-pmph）联合Padcev®（enfortumab vedotin-eifv）的疗法获得美国FDA批准 [1] - 获批疗法用于治疗患有肌层浸润性膀胱癌的成年患者，作为新辅助治疗并在膀胱切除术后继续作为辅助治疗 [1]